|
|
Support : Dialog Search Aids
: Pharmaprojects Therapeutic Class Codes
Pharmaprojects Therapeutic Class Codes
(DIALOG Files 128*, 928*)
*(Subscriber access.)
 View the PDF version of this document
This list includes the therapeutic categories
in order of their codes. This allows you to
see the hierarchy involved in the classification.
| I |
IMMUNOLOGICAL PRODUCTS |
| I1A |
IMMUNOSTIMULANT, ANTI-AIDS
General immunostimulants for use in AIDS include oligopeptides related to thymus hormones, polynucleotide preparations and polysaccharides. |
| I1Z |
IMMUNOSTIMULANT, OTHER
Products which boost the activity of, or stimulate production of, cells of the immune system, and those which non-specifically boost antibody production. Adjuvants are also included here. |
| I2 |
CYTOKINE
Cytokines are small, non-antibody proteins which act as intercellular mediators between an activated cell and another cell involved with the immune response. Cytokines in development include interferon preparations, colony stimulating factors and transforming growth factors. |
| I4A2 |
IMMUNOGLOBULIN, NON-MAB
Immunoglobulin preparations which are not targeted against specific antigens, as monoclonals are. Such preparations provide a boost to the immune system in the fight against an infection and may also be used prophylactically. |
| I5 |
IMMUNOSUPPRESSANT
Immunosuppressants have two major therapeutic functions. They may be used in the treatment of rejection following allogenic transplant, and they have potential in the therapy of autoimmune diseases. |
| I6Z |
IMMUNOLOGICAL
Compounds known to have an immunological action which has not yet been defined. Immunologically acting compounds which cannot easily be placed in one of the other categories in the I section. |
top
| J |
ANTI-INFECTIVE PRODUCTS |
| J1A |
TETRACYCLINE
Tetracyclines are bacteriostatic antibiotics and act by inhibiting bacterial protein synthesis by reversibly binding to the 30S portion of the bacterial ribosome. |
| J1C1 |
PENICILLIN, ORAL
Orally-active natural and semisynthetic derivatives of penicillanic acid. Penicillins are bactericidal, and act by inhibiting the formation of peptide cross-linkages in the final stage of bacterial cell wall synthesis. |
| J1C2 |
PENICILLIN, INJECTABLE
Injectable natural and semisynthetic derivatives of penicillanic acid. Penicillins are bactericidal, and act by inhibiting the formation of peptide cross-linkages in the final stage of bacterial cell wall synthesis. |
| J1D1 |
CEPHALOSPORIN, ORAL
Orally-active cephalosporins which are bacteriocidal and act by inhibiting the synthesis of the bacterial cell wall, critical for growth and development. Carbadethiacephalosporins and cephamycins are also classified here. |
| J1D2 |
CEPHALOSPORIN, INJECTABLE
Injectable cephalosporins which are bacteriocidal and act by inhibiting the synthesis of the bacterial cell wall, critical for growth and development. Carbadethiacephalosporins and cephamycins are also classified here. |
| J1E |
TRIMETHOPRIM AND ANALOGUE
Formulations, analogues and prodrugs of the dihydrofolate reductase inhibitor, trimethoprim. Trimethoprim is a bacteriostatic agent and acts by inhibiting the conversion of bacterial dihydrofolic acid to tetrahydrofolic acid which is necessary for the synthesis of bacterial DNA. |
| J1F |
MACROLIDE ANTIBIOTIC
Macrolide antibiotics, eg erythromycin, are mainly derived from streptomyces spp. and are bacteriostatic agents that act by inhibiting bacterial protein synthesis by reversibly binding to the 50S portion of the bacterial ribosome. |
| J1L |
AMINOGLYCOSIDE ANTIBIOTIC
Aminoglycoside antibiotics eg gentamicin, are mainly derived from streptomyces sp. and micromonospora and act by binding to the 30S portion of the bacterial ribosome and although they inhibit microbial protein synthesis, they are described as being bactericidal. |
| J1M |
PEPTIDE ANTIBIOTIC
Natural and semisynthetic antibiotics with a peptide structure, including glycopeptides. Glycopeptides are bactericidal agents which act by inhibiting bacterial cell wall synthesis. Other peptides have varied mechanisms of action. |
| J1N |
BETA-LACTAM ANTIBIOTIC
Antibiotics with a beta-lactam (penem) ring structure which are not penicillins, cephalosporins, or cephamycins. Beta-lactam antibiotics are bactericidal agents which act by binding to penicillin-binding proteins, and disrupting bacterial cell wall synthesis. |
| J1Z |
ANTIBIOTIC, OTHER
Novel antibiotics which cannot be placed in any of the antibiotic categories J1A to J1N or antibiotics for which the structure or mode of action is unknown. Beta-lactamase inhibitors are also found here. |
| J2A |
ANTIFUNGAL
Topical (dermatological) and systemic antifungal agents including squalene epoxidase inhibitors and mepartricin derivatives. |
| J3C |
QUINOLONE ANTIBACTERIAL
Antibacterial compounds which contain a quinolone or naphthyridine structure. Quinolones, eg ofloxacin, are bactericidal and act by inhibiting DNA gyrase — the enzyme responsible for maintaining the structure of DNA. |
| J3Z |
ANTIBACTERIAL, OTHER
Antibacterial compounds not classified under Quinolone antibacterial (J3C) and which are not antibiotics (J1 categories). |
| J4A |
ANTIMYCOBACTERIAL
Products that treat infections caused by mycobacteria which are responsible for tuberculosis, leprosy and MAC disease. New antimycobacterial products include isoniazid derivatives, rifamycin derivatives — such as rifabutin which inhibits the protein 50S ribosomal subunit — and inhibitors of mycobacterial dihyfrofolate reductase (DHFR). |
| J5A |
ANTIVIRAL, ANTI-HIV
Compounds for the treatment of infection with HIV including nucleoside analogues, non-nucleoside inhibitors of reverse transcriptase, inhibitors of the RNase actions of reverse transcriptase, TAT and HIV protease inhibitors. |
| J5B |
ANTIVIRAL, INTERFERON
All interferons, recombinant, natural and synthetic, and interferon inducers which are used against viral infections. New interferons under development for the treatment or prevention of viral infections include a -, b — and g -interferons, and also interferon inducers. |
| J5Z |
ANTIVIRAL, OTHER
Compounds that act specifically against viruses, except interferons and their analogues (see J5B), antivirals acting exclusively against HIV (J5A) and vaccines (J7A). Antivirals in development include inhibitors of herpes simplex ribonucleotide reductase, thymidine kinase inhibitors and rhinovirus protease inhibitors. Other new agents include humanized monoclonal antibodies and oligonucleotides. |
| J7A1 |
PROPHYLACTIC VACCINE
All preparations of antigenic materials which induce an immune response to specific bacteria or viruses which are used to prevent disease. It does not include therapeutic vaccines (J7A2), which are administered post-infection to limit disease. Cancer vaccines (K3) and contraceptive vaccines (G3C, G5C) are also not included in this section. Vaccines are inactivated live, attenuated, killed or recombinant forms of bacteria or viruses, in which infectivity is lost or reduced but antigenicity remains. They are often co-administered with adjuvant (see Immunostimulant, other (I1Z)) to boost or prolong the immune response. |
| J7A2 |
THERAPEUTIC VACCINE
All preparations of antigenic materials which are administered post-infection to induce an immune response to limit disease. Prophylactic vaccines (J7A1), cancer vaccines (K3) and contraceptive vaccines (G3C, G5C) are not included in this section. Vaccines are inactivated live, attenuated, killed or recombinant forms of bacteria or viruses, in which infectivity is lost or reduced but antigenicity remains. They are often co-administered with adjuvant (see Immunostimulant, other (I1Z)) to boost or prolong the immune response. |
| J7B |
IMMUNOMODULATOR, ANTI-INFECTIVE
Anti-infective compounds which also have immunostimulant, immunosuppressant or immunomodulatory activity. Includes antibodies linked to an anti-infective agent, cytokines with anti-infective immunomodulatory activity (except interferons and interferon-inducers (see J5B)) and anti-infective monoclonals (except anti-HIV monoclonals and monoclonals against HIV-infected cells (J5A) and other antiviral monoclonals (J5Z)). Does not include immunostimulants for which a specific activity has not yet been ascertained (see I1Z) or immunostimulants for use in AIDS (I1A). |
| J8Z |
ANTI-INFECTIVE, OTHER
All products that cannot be placed in any of the other anti-infective categories (J1A-J7B). These products act against microbial organisms, but it is not specified whether these products act against bacteria, fungi and/or viruses. Also included are agents which protect against prion (infectious proteins) infection. |
Last modified on 24 Feb 2012.
top
|
Related Search Aid:
Pharmaprojects (DIALOG Files 128, 928) Major Events in the Update Information (UP) Field
|
Dialog1
Support Home